ライフサイエンスコーパス: second-line chemotherapy

1 e interviewed in relation to both first- and second-line chemotherapy).

2 eritoneal lymph node dissection (RPLND), and second-line chemotherapy.

3 many as 20% to 30% of patients never receive second-line chemotherapy.

4 time that a solid tumor had been cured with second-line chemotherapy.

5 the phase 3 PROMISE-meso trial compared with second-line chemotherapy.

6 e treated at Indiana University with VeIP as second-line chemotherapy.

7 men, but no robust evidence is available for second-line chemotherapy.

8 on demonstrated synergy with both first- and second-line chemotherapy.

9 We also analysed the second-line chemotherapy.

10 s as surrogates for OS in patients receiving second-line chemotherapy.

11 irst-line chemotherapy and 47 in relation to second-line chemotherapy (15 patients were interviewed i

12 or markers after first-line (50 patients) or second-line chemotherapy (64 patients) who underwent PCR

13 clinical trial end points, the prevalence of second-line chemotherapy administration, the role of tre

14 uperior to survival previously reported with second-line chemotherapy, and is similar to the results

15 25 levels less than 35 U/mL after initial or second-line chemotherapy, and relapsed more than 6 month

16 year with the approval of a vaccine therapy, second-line chemotherapy, and reported survival advantag

17 to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendatio

18 ourse is also acceptable, with initiation of second-line chemotherapy at disease progression.

19 mised-controlled trials suggest a benefit of second-line chemotherapy compared with supportive care a

20 Second-line chemotherapy consisted of paclitaxel 135 mg/

21 e younger, can be successfully salvaged with second-line chemotherapy followed by allogeneic stem cel

22 Patients receiving second-line chemotherapy followed by resection had signi

23 Patients undergoing second-line chemotherapy followed by resection have a po

24 col encompassing dose-dense and dose-intense second-line chemotherapy, followed by HDT and ASCT, are

25 emoglobin </= 11.0 g/dL, receiving first- or second-line chemotherapy for metastatic breast cancer, w

26 For patients without progression, timing of second-line chemotherapy for optimum clinical benefit re

27 Second-line chemotherapy for patients with oesophagogast

28 combination with ifosfamide and cisplatin as second-line chemotherapy for patients with relapsed test

29 urgery, secondary or interval cytoreduction, second-line chemotherapy, hormonal therapy, and immunoth

30 and ixabepilone each have modest activity as second-line chemotherapy in docetaxel-refractory castrat

31 The addition of high-dose CBX to second-line chemotherapy in NSCLC cannot be recommended.

32 boplatin is increasingly used as initial and second-line chemotherapy of ovarian cancer and other mal

33 extracranial metastatic sites) and no prior second-line chemotherapy or brain-directed therapy were

34 r, lymphoma, or myeloma, referred for first-/second-line chemotherapy or immunotherapy or targeted th

35 ine chemotherapy v 43%, n = 20 being offered second-line chemotherapy; P = .006).

36 at first-line chemotherapy v 43%, n = 20 at second-line chemotherapy; P = .06).

37 Salvage therapy was successful with second-line chemotherapy/radiation and autologous stem-c

38 or PFS and OS, adverse factors were use of a second-line chemotherapy regimen and interval of more th

39 ing ifosfamide, carboplatin, etoposide (ICE) second-line chemotherapy (SLT) followed by high-dose the

40 k of a head-to-head comparison with standard second-line chemotherapy, they are now recommended for p

41 Women offered second-line chemotherapy were more likely to undergo che

42 mary refractory aggressive NHL who underwent second-line chemotherapy with ICE with the intent of adm

43 ary refractory aggressive NHL should receive second-line chemotherapy, with the intent of administeri